Why the study?
Does chronic renal failure alter the anticoagulant half-life of intravenous heparin compared to normal renal function?
Does chronic renal failure alter the anticoagulant half-life of intravenous heparin compared to normal renal function?
Heparin half-life is dose-dependent and prolonged in chronic renal failure, which can inform constant infusion dosage schedules.
Answers are grounded in this paper and cite their sources.
May inform heparin dosing adjustments in chronic renal failure; leaves open validation in larger studies.
The half‐life of heparin was calculated in persons with normal renal function and in patients in chronic renal failure. Intravenous heparin, 0.3 and 0.6 U/ml of blood volume, was administered. The anticoagulant half‐life of heparin was found to be dose‐related. The normal renal function group gave a mean anticoagulant half‐life of 36.S minutes for the 0.6 U/ml dose and 22.7 minutes for the 0.3 U/ml dose. The chronic renal failure population had a mean half‐life of 47.5 minutes for the 0.6 U/ml dose and a mean half‐life of 32.6 minutes for the 0.3 U/ml dose. By use of the equations of first‐order pharmacokinetics, a heparin dosage schedule was derived through which anticoagulation of patients can proceed by means of constant infusion of the drug. The schedule not only is applicable to patients in renal failure but also may be used in heparinization of patients with normal renal function.
No takes yet. Share an insight, caveat, or question.
Perry et al. (1974) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: